Long-term adverse effects of benzodiazepine use





Alzheimer Disease; Anxiolytic agent; Long Term Adverse Effects.


Benzodiazepines (BZD) are drugs whose main clinical indications are associated with anxiety, insomnia, muscle relaxation, relief of spasticity caused by central nervous system pathology, and epilepsy. The main adverse effects related to long-term use of BZD are memory loss, decline in cognitive function, imbalance, and reduced judgment. This is an integrative review based on searches of the SCIELO, PUBMED, and VHL databases, using the following inclusion criteria: articles published in the last 5 years, free full text, answering the guiding question, and written in English, Portuguese, or Spanish. For the review, 10 articles were selected and analyzed according to the pattern of the most common adverse effects, which are: suicidal and self-injurious behavior, delirium, overdoses, paralytic ileus, myopathies, triglyceride elevation, and ocular signs and symptoms. The profile of patients in long-term BZD use is female, with low education and greater clinical impairments. Furthermore, an association between chronic BZD use and hippocampal atrophy, representing the pattern of Alzheimer's disease, has been reported; however, a direct relationship cannot be stated. Since there is suspicion of neurodegeneration associated with the use of BZD, it is necessary to follow up with new studies in order to generate better quality of life, guaranteeing integral health care and preventing the aggravations related to the prolonged use of this medication.


Aldaz, P. et al. (2021). Association between benzodiazepine use and development of dementia. Medical clinic, 156, 107-111.

Chan, T. et al. (2017). Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study. Psychogeriatrics, 17 (5), 310–316.

Crossetti, M. D. G. O. (2012). Revisão integrativa de pesquisa na enfermagem o rigor cientifico que lhe é exigido. Revista Gaúcha de Enfermagem, 33 (2), 8-9.

Desmidt, T. et al. (2019). Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort. Neurobiology of Aging, 84, 61–69.

Dyer, A. H. et al. (2020). Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer’s Disease: Results From NILVAD. Journal of the American Medical Directors Association, 21 (2), 194–200.

Fiorelli, K. & Assini, F. L. (2017). A prescrição de benzodiazepínicos no Brasil: uma análise da literatura. ABCS health science, 42 (1), 40–44.

Fond, G. et al. (2017). Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. European Archives of Psychiatry and Clinical Neuroscience, 268 (1), 17–26.

Gallet, Q. et al. (2022). Benzodiazepine use and neuroimaging markers of Alzheimer’s disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 47 (5), 1114–1120.

Gamboa, P. A. T. & Ribeiro, M. M. (2019). Avaliação do volume do hipocampo no idoso em imagens de ressonância magnética: comparação de diferentes métodos de segmentação. Dissertação de mestrado (Mestrado em radiações aplicadas às tecnologias da saúde) – Instituto Politécnico de Lisboa, Lisboa.

Gil, A. C. (2018). Como elaborar projetos de pesquisa. (5ª ed.), São Paulo: Atlas.

Griffin, C. E. et al. (2013). Benzodiazepine pharmacology and central nervous system-mediated effects. The Ochsner journal, 13 (2), 214–23.

Guevara, G. P. (2014). O elevado do consumo de benzodiazepínicos. Trabalho de Conclusão de Curso (título de especialista em Saúde da Família) – Universidade do Estado do Rio de Janeiro, Rio de Janeiro.

Jenraumjit, R. et al. (2020). Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer’s disease: a 1 year follow-up study. BMC Research Notes, 13 (1).

Liu, M. et al. (2020). Hyperphosphorylated tau aggregation and cytotoxicity modulators screen identified prescription drugs linked to Alzheimer’s disease and cognitive functions. Scientific Reports, 10 (1), 16551.

Madruga, C. S. et al. (2018). Prevalence of and pathways to benzodiazepine use in Brazil: the role of depression, sleep, and sedentary lifestyle. Brazilian Journal of Psychiatry, 41 (1), 44–50.

Mendes, K. C. C. (2013). O uso prolongado de benzodiazepínicos - uma revisão de literatura. Trabalho de Conclusão de Curso (Especialização em Atenção Básica em Saúde da Família) - Universidade Federal de Minas Gerais, Pompéu-MG.

Olfson, M. & King, M. & Schoenbaum, M. (2015). Benzodiazepine use in the United States. JAMA Psychiatry, 72 (2), 136.

Richardson, K. et al. (2020). Neuropathological correlates of cumulative benzodiazepine and anticholinergic drug use. Journal of Alzheimer’s Disease, 74 (3), 999–1009.

Taipale, H. et al. (2020). Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland. JAMA Network Open, 3(10), e2019029.

Toyoshima, M. et al. (2021). Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system. International Journal of Medical Sciences, 18 (5), 1130–1136.



How to Cite

ALVES, A. N.; FREITAS, T. C. A. de; MACHADO, Y. C. Long-term adverse effects of benzodiazepine use. Research, Society and Development, [S. l.], v. 11, n. 14, p. e330111436322, 2022. DOI: 10.33448/rsd-v11i14.36322. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/36322. Acesso em: 9 dec. 2022.



Review Article